ABSTRACT

More detailed observation of deciding to provide thromboembolic prophylaxis which is the most important complication for patients with artrial fibrillation and choosing right agent.

Totally 300 patients who were under warfarin treatment with nonvalvuler AF diagnosis has been allocated in this study. The observation was hold to give correct anticoagulant therapy to eligible patients by evaluating patients by using CHA2DS2-VASC and HASBLED scoring systems and by calculating right indication and risk of bleeding calculation.

When we evaluate CHA2DS2-VASC scores of participants, 0 was observed as the lowest risk score, 9 as the highest score and 3.4067±1.76967 as average risk level. HASBLED point of participants was obtained at 2.11±1.178 level. 66% of participants got (n=198) 2 or lower scores, 34% of them got n=102) 3 or over.

In this study, we showed that patients receiving warfarin treatment started to use the medicine with correct indications, but they were not sufficiently evaulated with regard to side effects of the drug. In patients without high bleeding risk factors, using warfarin prophylaxis of venous thromboembolism in the presence of endication is indisputable. It is keeping its importance among alternatives for both providing the strongest anticoagulation effect with warfarin treatment and cost reasons. Although the use of new oral anticoagulant drugs are recently being discussed as an alternative, we obtained a conclusion that treatment decision should be made after the evaluation of patient convenience for warfarin treatment, considering that side effects and antidotes of new medicines are not known and that new medicines are not known and that new medicines have higher cost. (JAREM 2015; 5: 115-20)

Keywords: Warfarin, atrial fibrillation, accurate indication